PressJuly 23, 2024 Optimi Health to Enter Asian Market with PsiloThai Collaboration on Psilocybin Research
PressJuly 23, 2024 Awakn Life Sciences Provides Update on Aminoindane New Chemical Entity Patent Portfolio
PressJuly 23, 2024 Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression
PressJuly 20, 2024 HYTN Completes Acquisition of Prism Scientific Labs, Enhancing Psychedelic Compound Manufacturing Capabilities
PressJuly 20, 2024 Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
PressJuly 20, 2024 Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
PressJuly 20, 2024 Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15
PressJuly 17, 2024 MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)
PressJuly 17, 2024 Psyched Wellness Adds Harmons to List of Retail Partners, Engages UNFI For Distribution, and Announces Appointment of Kyle Nazareth as Chief Financial Officer
PressJuly 16, 2024 Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial
PressJuly 16, 2024 Braxia Scientific Announces Application for a Management Cease Trade Order For Late Filing of Audited Annual Financial Statements
PressJuly 16, 2024 Algernon Pharmaceuticals Reports Results of Study Showing 93% Cough Suppression with Ifenprodil
PressJuly 16, 2024 Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss
PressJuly 16, 2024 SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
Health & ScienceJuly 16, 2024 Braxia Scientific Corp. Delays Financial Report Amid Management Changes
PressJuly 12, 2024 Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
